GoodRx (NASDAQ:GDRX) Shares Gap Up – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $4.11, but opened at $4.26. GoodRx shares last traded at $4.46, with a volume of 627,638 shares traded.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Truist Financial reduced their price objective on GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. UBS Group reduced their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Wells Fargo & Company reduced their price objective on GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Finally, The Goldman Sachs Group reduced their price objective on GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.55.

GoodRx Stock Performance

The stock has a fifty day simple moving average of $4.25 and a 200-day simple moving average of $4.53. The stock has a market cap of $1.62 billion, a P/E ratio of -151.00, a PEG ratio of 2.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analysts’ expectations of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On GoodRx

Large investors have recently modified their holdings of the business. National Bank of Canada FI boosted its stake in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after buying an additional 2,151 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new position in shares of GoodRx during the 1st quarter worth about $44,000. RPO LLC acquired a new position in shares of GoodRx during the 4th quarter worth about $52,000. Jump Financial LLC acquired a new position in shares of GoodRx during the 1st quarter worth about $49,000. Finally, Versor Investments LP acquired a new position in shares of GoodRx during the 4th quarter worth about $54,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.